Peter M.J. Quinn

Assistant Professor of Ophthalmology and Principal Investigator of the PrimeSight Lab at the University of Pennsylvania. #CRB1 #PRPH2. Tweets are my own.

[Peter M.J. Quinn @PeterMJQuinn]

New Publication Alert from the PrimeSight Laboratory!

Thrilled to share our latest article: “Prime Editing for the Investigation of Aberrant Splicing Defect Associated with a Pathogenic PRPH2 Variant” is accepted in @MolTherapy Nucleic Acids.
#PRPH2 #PrimeEditing #RP #IRDs

[Molecular Therapy Family of Journals @MolTherapy]

Prime Editing for the Investigation of Aberrant Splicing Defect Associated with a Pathogenic PRPH2 Variant https://t.co/Va6xW9MUlo #MTNA

[Peter M.J. Quinn @PeterMJQuinn]

Thanks to all those that supported this research in some part including private donations, @CureCRB1, @FightBlindness, and @NatEyeInstitute

[Peter M.J. Quinn @PeterMJQuinn]

New Publication Alert from the PrimeSight Laboratory!

Thrilled to share our latest article: “Prime Editing for the Investigation of Aberrant Splicing Defect Associated with a Pathogenic PRPH2 Variant” is accepted in @MolTherapy Nucleic Acids.
#PRPH2 #PrimeEditing #RP #IRDs

[Molecular Therapy Family of Journals @MolTherapy]

Prime Editing for the Investigation of Aberrant Splicing Defect Associated with a Pathogenic PRPH2 Variant https://t.co/Va6xW9MUlo #MTNA

[Department of Ophthalmology & Scheie Eye Institute @ScheieEye]

Jose Ronaldo Lima de Carvalho, MD, a Research Associate working with faculty member @PeterMJQuinn, has received a prestigious research grant from the Knights Templar Eye Foundation!
https://t.co/fPXF4WOOgc
#ophthalmology #scheieeye #upenn #pennmedicine #research #visionscience

[Peter M.J. Quinn @PeterMJQuinn]

It was my pleasure to discuss therapeutic editing on International World CRISPR Day with the PRPH2 Grass Roots Community. Please listen to me discussing CRISPR technology on the Eye on the Cure podcast earlier this year. #CRISPR #CRB1 #PRPH2 #IRDs
https://t.co/rIV92JaROE

[Peter M.J. Quinn @PeterMJQuinn]

Job opportunity Quinn Lab: Postdoctoral Scientist Position in Gene Therapy and Disease Modeling. See link for details l.

https://t.co/sMG50x8rT5

[Peter M.J. Quinn @PeterMJQuinn]

Our data further highlights the impact of compensatory regulation between miR clusters with implications for the development of miR-based therapeutics.

[Peter M.J. Quinn @PeterMJQuinn]

Congratulations to Bruna and the Tsang Lab for their new publication in @BioMedCentral Cell & Bioscience. This is another manuscript I helped with during my time in the Tsang lab.
https://t.co/biFynToPSA

[Peter M.J. Quinn @PeterMJQuinn]

We elucidated the underlying mechanisms associated with the therapeutic modulation of miR-181a/b in retinitis pigmentosa, providing insights into the metabolic processes linked to its RPE-specific downregulation.

[Peter M.J. Quinn @PeterMJQuinn]

Our data further highlights the impact of compensatory regulation between miR clusters with implications for the development of miR-based therapeutics.

[Peter M.J. Quinn @PeterMJQuinn]

We elucidated the underlying mechanisms associated with the therapeutic modulation of miR-181a/b in retinitis pigmentosa, providing insights into the metabolic processes linked to its RPE-specific downregulation.

[LifeScienceAlliance @LSAjournal]

This study describes novel interactors of the retinal Crumbs complex and reveals homo- and heterotypic interactions of CRB1 and CRB2 that are not significantly affected by patient-associated mutations https://t.co/O3MwzXC0Fb

[Peter M.J. Quinn @PeterMJQuinn]

Thanks to @LSAjournal for the great publishing experince!

[Peter M.J. Quinn @PeterMJQuinn]

Happy to share a new manuscript in collaboration with the lab of Marius Ueffing. In this study, we investigated the interaction of canonical CRB1 and CRB2 in the retina. https://t.co/72hJUijTa0

[Peter M.J. Quinn @PeterMJQuinn]

Fourth, various patient-described missense mutations in CRB1 or CRB2 did not or only mildly altered the CRB1–CRB2 interaction in vitro, hinting toward a strong CRB1–CRB2 interaction.

[Peter M.J. Quinn @PeterMJQuinn]

Recent conference abstracts from the lab:

https://t.co/CexZE3pJJ1

https://t.co/CFkjgQZKOT

[Peter M.J. Quinn @PeterMJQuinn]

Hello Network, I am on the lookout for technicians and postdocs interested in pursuing work on multiple projects involved in developing therapies for inherited retinal diseases. Please direct message me if interested.

[Peter M.J. Quinn @PeterMJQuinn]

The work will involve developing edited cell lines, iPSC-derived retinal organoid disease modeling, iPSC-derived retinal pigment epithelium disease modeling, and the development of prime editing viral and non-viral tools.